Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory
tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which
has been particularly problematic to eradicate and been implicated as the major cause of
morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung
increases the local concentrations of antibiotic at the site of infection resulting in
improved antimicrobial effects compared to systemic administration. Bacterial resistance to
current aerosol antibiotic treatments indicate a need for improved therapies to treat CF
patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and
other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to
have antimicrobial effects on even the most resistant organisms.